Pharma Marketing News
PMN Home | Advertising Information | FAQs
About Us | Contact Us | Privacy Policy
Subscribe Glossary
Pharma Marketing Blog Pharmaguy Audio Podcasts Event Calendar PReader Surveys
Share |

Do TV DTC Ads Overstate Rx Drug Risks?
FDA Poised to Tip Balance in Favor of Benefits

Benes v. Risks Tipping Balance On Valentine's Day 2014, FDA sent the drug industry a love letter in the form of a Federal Register submission (published later on 18 February 2014; Docket No. FDA-2014-N-0168) proposing a study of disclosure of "additional" risks in direct-to-consumer (DTC) prescription drug television advertisements.

Specifically, FDA intends to look for evidence that the "major statement" of drug risks as currently implemented in DTC TV ads is often too long and "may result in reduced consumer comprehension, minimization of important risk information and, potentially, therapeutic noncompliance due to fear of side effects."

Subjects include (partial list):
  • FDA Letters Often Cite Risk Minimization
  • A Little History of Risk Communication
  • Consumers Less Concerned than Docs
  • Risk-First DTC
  • Risk Straight Talk
  • DTC Without the Risk
  • More Risk Information, Better DTC Ads?
  • More Risk Information, Better Sales?
  • Risk After DTC
  • Public Citizen Petitions FDA for a Black Box Warning on Testosterone Products
Download the full text PDF file here:

Issue: Vol. 13, No. 2: February 2014

Find other articles in related Topic Areas:

Vol 13, #2 Contents

Contact Information
Pharma Marketing News

Pharma Marketing News | Subscribe | Industry Insights | Podcasts | Pharmaguy | Blog
Surveys | Glossary | Conference Calendar | Advertising Information | FAQs | About Us | Privacy Policy

© 2014. Pharma Marketing Network. All rights reserved.